

## Special Issue

# Leveraging Immune Checkpoint Blockades-Based Combined Therapy to Overcome Adaptive Immune Resistance

### Message from the Guest Editor

Tumors employ various tactics to adapt to and eventually resist immune attack, collectively called adaptive immune resistance (AIR). Despite the recent success of immune checkpoint blockades (ICBs) that were found to induce systemic regression of tumors and prolong survival, AIR has held the field back from wider success. As ICBs can treat subsets of 'inflamed' cancers infiltrated by pre-primed tumor-reactive T cells, several novel approaches (such as CAR-T, oncolytic virus, and cancer vaccines) have the potential to newly prime tumor-reactive T cells. Therefore, combining ICBs with novel immunotherapy would lead to enhanced treatment of a larger fraction of human cancers in the near future. Based on your expertise in cancer immunotherapy, you are invited to contribute a research paper or review in this Special Issue to highlight the remaining challenges for translation medicine to achieve a selective and durable anti-tumor immune response in advanced cancer patients. Studies focusing on ICBs and adaptive immune resistance through both clinical and pre-clinical investigations are welcome.

### Guest Editor

Dr. Chunchao Zhu

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200232, China

### Deadline for manuscript submissions

closed (31 October 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/151315](https://mdpi.com/si/151315)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).